Original Article
Efficacy and Safety of Epoetin Alfa in Critically Ill Patients
N Engl J Med 2007; 357:965-976September 6, 2007
- Abstract
Background
Anemia, which is common in the critically ill, is often treated with red-cell transfusions, which are associated with poor clinical outcomes. We hypothesized that therapy with recombinant human erythropoietin (epoetin alfa) might reduce the need for red-cell transfusions.
Methods
In this prospective, randomized, placebo-controlled trial, we enrolled 1460 medical, surgical, or trauma patients between 48 and 96 hours after admission to the intensive care unit. Epoetin alfa (40,000 U) or placebo was administered weekly, for a maximum of 3 weeks; patients were followed for 140 days. The primary end point was the percentage of patients who received a red-cell transfusion. Secondary end points were the number of red-cell units transfused, mortality, and the change in hemoglobin concentration from baseline.
Results
As compared with the use of placebo, epoetin alfa therapy did not result in a decrease in either the number of patients who received a red-cell transfusion (relative risk for the epoetin alfa group vs. the placebo group, 0.95; 95% confidence interval [CI], 0.85 to 1.06) or the mean (±SD) number of red-cell units transfused (4.5±4.6 units in the epoetin alfa group and 4.3±4.8 units in the placebo group, P=0.42). However, the hemoglobin concentration at day 29 increased more in the epoetin alfa group than in the placebo group (1.6±2.0 g per deciliter vs. 1.2±1.8 g per deciliter, P<0.001). Mortality tended to be lower at day 29 among patients receiving epoetin alfa (adjusted hazard ratio, 0.79; 95% CI, 0.56 to 1.10); this effect was also seen in prespecified analyses in those with a diagnosis of trauma (adjusted hazard ratio, 0.37; 95% CI, 0.19 to 0.72). A similar pattern was seen at day 140 (adjusted hazard ratio, 0.86; 95% CI, 0.65 to 1.13), particularly in those with trauma (adjusted hazard ratio, 0.40; 95% CI, 0.23 to 0.69). As compared with placebo, epoetin alfa was associated with a significant increase in the incidence of thrombotic events (hazard ratio, 1.41; 95% CI, 1.06 to 1.86).
Conclusions
The use of epoetin alfa does not reduce the incidence of red-cell transfusion among critically ill patients, but it may reduce mortality in patients with trauma. Treatment with epoetin alfa is associated with an increase in the incidence of thrombotic events. (ClinicalTrials.gov number, NCT00091910.)
Media in This Article
Figure 1
Screening and Enrollment of Study Patients.Figure 2
Kaplan–Meier Estimates of Mortality through Day 29 for the 733 Patients Receiving Epoetin Alfa and the 727 Patients Receiving Placebo.Article Activity
- Article
Anemia is common in the critically ill, often resulting in red-cell transfusions.1,2 Two observational studies reported that 35 to 45% of patients admitted to intensive care units (ICUs) receive transfusions of almost 5 red-cell units while in the ICU.3,4 However, the view that red-cell transfusion is beneficial for critically ill patients has been questioned because of data suggesting that red-cell transfusion may decrease the likelihood of survival in critically ill adults.5-8
Anemia is evident early in the courses of critical illnesses, and hemoglobin concentrations fall throughout stays in the ICU.1,4 Impaired production of red cells contributes to the development and persistence of anemia. Although there are multiple reasons for this anemia, it has characteristics similar to the anemia of chronic inflammatory disease.9 A feature of anemia of critical illness is a lack of appropriate elevation of circulating erythropoietin concentrations in response to physiological stimuli.2,10 Such observations suggest that the administration of recombinant human erythropoietin (epoetin alfa) might raise hemoglobin concentrations in critically ill patients, thereby preventing the need for exposure to allogeneic blood.
We previously conducted two trials of the efficacy of epoetin alfa in reducing the number of red-cell transfusions.11,12 Both trials showed that treatment with epoetin alfa decreased the number of red-cell transfusions and increased hemoglobin concentrations. No other clinical benefits were found. We designed the current study to assess the safety and efficacy of a reduced dose of epoetin alfa and to evaluate clinical outcomes and subgroup differences suggested by our previous studies of critically ill patients.
Methods
General Description
We conducted this prospective, randomized, double-blind, placebo-controlled trial at 115 medical centers between December 2003 and June 2006. It was approved by the institutional review committee at each participating institution, and written informed consent was obtained from each patient (or his or her surrogate). If a surrogate provided consent, patients were approached for written informed consent when it was medically appropriate. An independent data and safety monitoring board monitored the safety of the study.
The two academic authors who were the principal investigators designed the study in conjunction with the clinical research organization and the sponsor. Patient enrollment and data collection were done at each site and supervised by the clinical research organization, which provided randomization and initial data analysis. The authors analyzed, interpreted, and had full access to the data; were responsible for the manuscript; and verify the completeness and accuracy of the data. An independent statistical consultant reviewed the statistical methods and data analyses. The final manuscript was written by the authors and reviewed by the sponsor.
Study Population
All patients who were admitted to medical, surgical, or medical–surgical ICUs in each of the participating institutions and remained in that ICU for 2 days were evaluated for eligibility. Other inclusion criteria were as follows: age of 18 years or older, hemoglobin concentration of less than 12 g per deciliter, and written informed consent. Exclusion criteria were as follows: expected discharge from the ICU within 48 hours after the second day in the ICU; acute ischemic heart disease (myocardial infarction or unstable angina) during the ICU stay; a stay of more than 48 hours' duration in the ICU of a transferring hospital; presence of a left ventricular assist device; history of pulmonary embolus, deep venous thrombosis, ischemic stroke, other arterial or venous thrombotic event (excluding superficial thrombosis), or a chronic hypercoagulable disorder; dialysis for any indication; uncontrolled hypertension (systolic blood pressure of >200 mm Hg or diastolic blood pressure of >110 mm Hg) after adequate antihypertensive therapy; new-onset seizures within the past 3 months or seizures not controlled by medication; third-degree burns on more than 20% of the body-surface area; pregnancy or lactation; diagnosis of acute, clinically significant gastrointestinal bleeding on admission; transfusion at the time of planned enrollment; treatment with epoetin alfa within the past 30 days; inability or unwillingness to receive blood products; participation in another study; and hypersensitivity to epoetin alfa or any of its components.
Randomization was performed between 48 and 96 hours after admission to the ICU (study day 1). Randomization was achieved with the use of computer-generated random numbers and was stratified according to site and three mutually exclusive admission groups (trauma, surgical nontrauma, and medical nontrauma).
Study Design
The study drug (epoetin alfa [Procrit, Ortho Biotech], 40,000 U) or an identical-appearing placebo was administered by means of subcutaneous injection on study day 1 and weekly thereafter, for a total of three doses (on days 1, 8, and 15), in patients remaining in the hospital. The study drug was withheld from patients with hemoglobin concentrations of 12 g per deciliter or greater at the time at which the second or third dose would have been given. All patients received liquid iron (150 mg elemental iron per day) by mouth or by nasogastric tube beginning on day 1 or when they could tolerate oral feeding. Parenteral iron was given if the response to the oral iron was inadequate (i.e., transferrin saturation, <20%; and serum ferritin concentration, <100 ng per milliliter).
The need for red-cell transfusion was determined by each patient's treating physician. Red-cell transfusion was targeted to maintain a hemoglobin concentration between 7 g per deciliter and 9 g per deciliter; transfusion was not recommended if the hemoglobin concentration was 9 g per deciliter or more or the hematocrit was 27% or greater, unless there was a specific clinical indication (e.g., active bleeding or ischemia). Transfusion in patients with a hemoglobin concentration of less than 9 g per deciliter or a hematocrit of less than 27% was undertaken at the discretion of the physician. There was no hemoglobin concentration or hematocrit that mandated a red-cell transfusion.
Study Outcomes
The primary end point was the percentage of patients receiving any red-cell transfusion between days 1 and 29. Secondary end points were the number of red-cell units transfused between days 1 and 42, mortality at day 29 and at day 140, and the change in hemoglobin concentration from baseline to day 29. Reports of all adverse events were collected through day 140.
Statistical Analysis
On the basis of our previous trials,11,12 we calculated that 1300 patients would be required for the study to have a statistical power of 80% to detect an absolute difference of 8% in the primary end point between the epoetin alfa group and the placebo group. According to the results of a blinded review during the current study, the protocol was amended in order to maintain the planned statistical power, and we increased the number of patients by 160, for a total of 1460 patients. All patients were followed for 140 days, unless death occurred earlier. Statistical analyses were based on the intention-to-treat principle and involved all patients who had undergone randomization.
The primary end point, the percentage of patients receiving a red-cell transfusion, was evaluated with the use of the Cochran–Mantel–Haenszel test, stratified according to the admission group (trauma, surgical nontrauma, or medical nontrauma), which was prespecified. Patients who had not yet received a transfusion when they discontinued the study drug or were lost to follow-up were considered not to have received a transfusion during the study period. Another evaluation was performed, which was identical except that patients who discontinued the study drug or were lost to follow-up were considered to have received a transfusion. Relative risks and their 95% confidence intervals were calculated.
The numbers of red-cell units transfused were compared between the epoetin alfa group and the placebo group with the use of the Wilcoxon–Mann–Whitney test. The transfusion rate was expressed as the number of units that were transfused for a given patient divided by the total number of days the patient was alive. The change in hemoglobin concentration from baseline was compared between the two groups with the use of an analysis of covariance, with the effects of baseline hemoglobin value, admission group, and study group included in the model. We imputed missing values using the last-observation-carried-forward method.
Mortality data were analyzed with the use of the stratified Kaplan–Meier method, evaluated at days 29 and 140. The Greenwood formula was used to calculate the corresponding standard error for the survival rate, and the inverse-variance approach was used to standardize the test statistics accounting for the three strata (trauma, medical nontrauma, and surgical nontrauma) (see the Supplementary Appendix, available with the full text of this article at www.nejm.org). We believed that this Kaplan–Meier approach was more appropriate than the log-rank test, because approximately 90% of the patients did not die during the study and, as a result, there was a large percentage of data censored. A permutation test was done to confirm the robustness of the analysis. Data for time to death were censored at the date of the last assessment if a patient was withdrawn before day 140. Data were censored at day 140 for patients who were alive at the end of the study period.
We evaluated the interaction between the study group (epoetin alfa or placebo) and the admission group (trauma, medical nontrauma, or surgical nontrauma) using a Cox regression model including study group, admission group, and the interaction between the study group and the admission group. A Cox regression analysis was also performed to adjust hazard ratios for mortality, with several covariates: age; sex; admission group; types of coexisting conditions; score on the Acute Physiology and Chronic Health Evaluation II; baseline hemoglobin concentration, iron studies, erythropoietin concentration, and serum creatinine concentration; and Injury Severity Score. The unadjusted hazard ratio was also determined.
We studied the use of mechanical ventilation by analyzing the numbers of ventilator-free days and the duration of mechanical ventilation. Kaplan–Meier estimates were calculated in addition to descriptive statistics. Lengths of stay in the ICU and hospital were analyzed in a similar manner to mechanical ventilation.
Analyses according to the prospectively identified admission group (trauma, surgical nontrauma, and medical nontrauma) were performed similarly to those in the overall population. The final analyses were based on a two-sided significance level of 0.05.
Results
Study Population
We enrolled 1460 patients, of whom 733 were randomly assigned to receive epoetin alfa and 727 to receive placebo (Figure 1Figure 1
Screening and Enrollment of Study Patients.). In total, 94.3% of patients completed the study through day 29 (95.2% of patients in the epoetin alfa group and 93.4% of patients in the placebo group), 90.9% through day 42 (93.2% and 88.6%, respectively), and 82.9% through day 140 (84.3% and 81.6%, respectively). Overall, 140 patients (9.5%) discontinued the study drug: 61 patients in the epoetin alfa group (8.3%) and 79 in the placebo group (10.9%). Five of these patients died after discontinuation (three in the epoetin alfa group and two in the placebo group). A total of 109 patients (7.5%) were lost to follow-up, 55 in the placebo group (7.6%) and 54 in the epoetin alfa group (7.4%).After the study was completed and the database was locked, we established the status of 26 of the 109 patients who had been lost to follow-up (11 in the epoetin alfa group and 15 in the placebo group). Of these 26, 5 patients had died (3 in the epoetin alfa group and 2 in the placebo group). In our analyses, these 26 patients were considered to be lost to follow-up.
The characteristics of the patients in the two study groups were similar at enrollment (Table 1Table 1
Baseline Characteristics.). However, surgical patients and medical patients were older than trauma patients (mean age [±SD], 64±14 years and 60±16 years, respectively, vs. 41±17 years) and more had one or more coexisting conditions (89.1% and 89.3%, respectively, vs. 32.2%). Within each of the three admission groups, patients in the epoetin alfa group and the placebo group had similar baseline characteristics.Among patients receiving epoetin alfa, 28.2% received one dose during the study, 32.2% received two doses, and 38.9% received three doses. Twelve patients (seven in the placebo group and five in the epoetin alfa group) did not receive study medication.
Red-Cell Transfusion
There was no significant difference between the groups in the percentage of patients who received a red-cell transfusion (46.0% in the epoetin alfa group vs. 48.3% in the placebo group; relative risk, 0.95; 95% confidence interval [CI], 0.85 to 1.06; P=0.34) (Table 2Table 2
Summary of Data on Red-Cell Transfusion.). Among patients who received a red-cell transfusion, there was no significant difference between the epoetin alfa group and the placebo group for the trauma patients, for the surgical nontrauma patients, or for the medical nontrauma patients. In the analysis in which patients who discontinued the study drug or were lost to follow-up were considered to have received a transfusion, there were fewer patients receiving a transfusion in the epoetin alfa group than in the placebo group (52.7% vs. 57.1%; relative risk, 0.92; 95% CI, 0.84 to 1.01; P=0.08). There was no significant difference between the two study groups in the total number of red-cell units transfused or the transfusion rate (Table 2).Transfusion practices appeared to be similar in the two study groups. The mean pretransfusion hemoglobin concentration was 8.0±1.0 g per deciliter in the placebo group and 8.2±0.9 g per deciliter in the epoetin alfa group, and the hemoglobin concentrations before the first transfusion and at subsequent transfusions were similar. Only 13.4% of patients received a transfusion when their hemoglobin concentration was above 9.0 g per deciliter. A total of 74.8% of patients in the epoetin alfa group and 77.2% in the placebo group received red-cell transfusions to maintain a hemoglobin concentration between 7 g per deciliter and 9 g per deciliter. A total of 11.4% of patients in the placebo group and 11.6% in the epoetin alfa group received transfusions for acute bleeding. Before randomization, 56.2% of patients (54.6% in the placebo group and 57.8% in the epoetin alfa group, P=0.27) received 1 or more red-cell units (5.9±7.2 in the placebo group and 6.3±7.3 in the epoetin alfa group, P=0.43).
Hemoglobin Concentration
At day 29, the increase in the hemoglobin concentration from baseline was greater in the epoetin alfa group than in the placebo group (1.6±2.0 g per deciliter vs. 1.2±1.8 g per deciliter, P<0.001), as was the absolute hemoglobin concentration (11.2±1.8 g per deciliter vs. 10.8±1.7 g per deciliter, P<0.001). By day 42, the hemoglobin concentrations in the two study groups were not significantly different. The reticulocyte count increased, paralleling the increase in the hemoglobin concentration during the study, peaking at day 22.
Mortality
Mortality at day 29 (Figure 2Figure 2
Kaplan–Meier Estimates of Mortality through Day 29 for the 733 Patients Receiving Epoetin Alfa and the 727 Patients Receiving Placebo.) was significantly lower in the epoetin alfa group than in the placebo group (8.5% vs. 11.4%, P=0.02), according to Kaplan–Meier estimates. In the trauma group, mortality was also significantly lower in the epoetin alfa group than in the placebo group (3.5% vs. 6.6%, P=0.04). The mortality pattern was similar at day 140, both among all patients (14.2% in the epoetin alfa group vs. 16.8% in the placebo group, P=0.08) and among the trauma patients alone (6.0% vs. 9.2%, P=0.08). In the Cox model, the hazard ratios for mortality in the overall population tended toward significance; the mortality hazard ratios for the trauma patients were significant at day 29 and day 140 (Table 3Table 3
Mortality at Day 29 and Day 140 in the Intention-to-Treat Population.). The interaction between the admission group and study group was not significant (P=0.16), confirming that our findings regarding mortality are consistent among the three admission groups.The trauma patients in the epoetin alfa group and those in the placebo group had similar baseline characteristics, including those related to trauma (Table 1). There was no relationship between the survival outcome with epoetin alfa and the Injury Severity Score, the score on the Glasgow Coma Scale, or the diagnosis on admission.
Adverse Events
At least one adverse event occurred in 94.4% of patients in the placebo group and in 94.8% of patients in the epoetin alfa group. Similarly, 43.5% of patients receiving placebo and 44.0% of those receiving epoetin alfa had a serious adverse event (Table 4Table 4
Serious Adverse Events.). There was an increased incidence of thrombotic vascular events among the patients in the epoetin alfa group as compared with those in the placebo group (16.5% vs. 11.5%; hazard ratio, 1.41; 95% CI, 1.06 to 1.86; P=0.008). Post hoc analyses showed that the incidence of thrombotic vascular events in the epoetin alfa group as compared with the placebo group was increased among patients who did not receive heparin at baseline (20.3% vs. 12.8%; hazard ratio, 1.58; 95% CI, 1.09 to 2.28; P=0.008) but not among those who received heparin at baseline (12.3% vs. 10.2%; hazard ratio, 1.16; 95% CI, 0.75 to 1.80; P=0.41). Similar trends in thrombotic vascular events were found among patients in each of the three admission groups. The increase in the incidence of thrombotic vascular events was most apparent among patients who received three doses of epoetin alfa, as compared with those who received three doses of placebo (22.8% vs. 16.1%, P=0.048), although the trend was similar (albeit not significant) for those receiving one dose (11.1% vs. 6.5%, P=0.31) and for those receiving two doses (13.6% vs. 9.5%, P=0.19).One patient who received a single dose of epoetin alfa tested positive for antibodies to erythropoietin at day 7 and day 140. A follow-up blood specimen collected on day 240 was positive for antibodies to erythropoietin but negative for erythropoietin-neutralizing antibody, which was not tested for on day 7 and day 140. That patient had no adverse outcomes.
Length of Stay and Use of Mechanical Ventilation
There was no significant difference between the epoetin alfa group and the placebo group in the median lengths of stay in the ICU (8 days and 7 days, respectively; P=0.43) and in the hospital (15 days in both groups, P=0.43).
At day 140, mechanical ventilation had been discontinued for 96.6% of patients receiving epoetin alfa and 98.4% of patients receiving placebo (P=0.02). However, the epoetin alfa group and the placebo group had a similar number of ventilator-free days (29.0±15.5 and 28.7±14.9, respectively; P=0.72) and a similar median duration of mechanical ventilation (15 days and 14 days, respectively; P=0.16).
Discussion
Two previous trials involving critically ill patients showed that treatment with epoetin alfa reduced the number of red-cell transfusions and raised the hemoglobin concentration.11,12 In the present study, we found no reduction in the incidence of red-cell transfusions in the epoetin alfa group, an unexpected finding. A likely explanation for this lack of reduction is a change in transfusion practice. In the previous trials, the mean pretransfusion hemoglobin concentration was 8.5 g per deciliter, consistent with observational studies at the time.3,4 In the present study, the mean pretransfusion hemoglobin concentration was 0.5 g per deciliter lower, at 8.0 g per deciliter.
The percentage of patients in the placebo group who received a transfusion fell from 60% in the previous trials to approximately 50%, similar to the percentage of patients in the epoetin alfa group who received a red-cell transfusion in this study and in the earlier trials.11,12 The decrease in the percentage of patients receiving a transfusion was greatest among medical and surgical patients, who had a 20% decrease as compared with those reported in prior trials. Our results suggest that efforts to limit transfusion in the critically ill, made after the publication of the Transfusion Requirements in Critical Care (TRICC) trial,5 have affected clinical practice. Our finding that patients who received epoetin alfa therapy had a greater increase in hemoglobin concentration than those who received placebo suggests that epoetin alfa had the expected hematopoietic effect, despite the lack of a reduction in the incidence of transfusion.
The most important finding in the current trial is the reduction in mortality among patients who received epoetin alfa as compared with those who received placebo, which was most apparent in the trauma patients. Our previous trial12 also showed decreased mortality among trauma patients treated with epoetin alfa as compared with placebo (4.8% vs. 10.4%; odds ratio, 0.43; 95% CI, 0.23 to 0.81). In that trial, the trauma, surgical nontrauma, and medical nontrauma admission groups were not prospectively identified, nor was randomization stratified according to these groups. As a result, patients within these groups who received epoetin alfa were not necessarily similar to those who received placebo, and multivariate analysis suggested that mortality was not affected by study group or admission group.
In the current trial, randomization was stratified according to the admission group identified in the earlier trial. The decreased mortality that we found among trauma patients who received epoetin alfa in the previous trial was replicated in the present trial: the study groups were similar, and the decreased mortality was confirmed by the adjusted hazard ratio. Taken together, the previous and present trials suggest a decreased mortality with epoetin alfa for trauma patients who are in the ICU for more than 48 hours. In contrast, no significant reduction in mortality was seen among surgical and medical patients receiving epoetin alfa. It is unclear whether this is because the study was underpowered for nontrauma patients or whether in fact only certain subgroups within the medical or surgical populations have a benefit.
Our prestudy hypothesis was that improvement in clinical outcome with the use of epoetin alfa would result from the prevention of adverse effects of transfused red cells. This was clearly not the case. The reduction in mortality was found in the absence of a reduction in the incidence of transfusion. Similarly, the timing of both the decreased mortality and the moderate degree of increase in hemoglobin concentration makes it unlikely that the increase in hemoglobin was responsible for the reduction in mortality. A more likely explanation is nonhematopoietic effects of epoetin alfa.
Erythropoietin has actions other than stimulation of the bone marrow to produce mature erythrocytes. It acts as a cytokine with antiapoptotic activity.13-15 In this role, erythropoietin has been shown in preclinical and small clinical studies to protect cells from hypoxemia and ischemia. Multiple tissues express erythropoietin and the erythropoietin receptor in response to stress and also to mediate local stress responses. These nonhematopoietic activities of erythropoietin in the protection of cells suggest a role for erythropoietin in critically ill patients.13 Apoptosis is important in the pathogenesis of many critical illnesses, such as sepsis and multiple-organ failure. Similar mechanisms may also be involved in mediating injury in trauma patients. Could the antiapoptotic activity of erythropoietin result in improved outcomes in critically ill patients? Although our current study does raise this possibility, further preclinical and clinical studies will be necessary to establish the mechanism responsible for the effects of epoetin alfa.
Trials in other populations (patients with cancer and those with chronic renal failure) that aimed to achieve target hemoglobin concentrations above 12 g per deciliter with the use of epoetin alfa have reported an increase in the risk of thrombotic complications and death.16-19 Patients with a history of thrombotic events were excluded from the present trial; however, we still observed an increase in the incidence of thrombotic events with epoetin alfa. In contrast to studies of erythropoietin in patients with cancer and those with renal failure, the findings in this trial are notable in two respects: first, the increase in the incidence of thrombotic events occurred with a hemoglobin target below 12 g per deciliter; and second, the duration of therapy was brief (three or fewer doses). A post hoc analysis did not show an increase in the incidence of thrombotic events among patients receiving epoetin alfa who also received heparin (prophylactic or therapeutic). An increase in the incidence of thrombotic events was not noted in our previous trials.11,12
In conclusion, despite the lack of reduction in the incidence of red-cell transfusion, we found a decrease in mortality among trauma patients who received epoetin alfa, consistent with our previous observations.12 This may suggest that epoetin alfa has actions distinct from hematopoiesis. On the basis of the available data, we believe that epoetin alfa could benefit trauma patients remaining in an ICU for more than 48 hours and who have hemoglobin concentrations below 12 g per deciliter and no history of thrombotic disease, provided they meet all the other inclusion criteria and do not have any of the exclusion criteria in the study. However, our present data suggest that, without further study, epoetin alfa should not be administered before a patient has been in the ICU for 48 hours, since administration early in the course may alter the risk–benefit ratio. The use of epoetin alfa is not supported for patients admitted to the ICU with a nontraumatic surgical or medical diagnosis, unless they have an approved indication for epoetin alfa.
Further study is needed to explore possible mechanisms that are responsible for the effects of epoetin alfa and to determine whether other critically ill patients might benefit from epoetin alfa therapy. Furthermore, our results increase the concern about thrombotic complications associated with epoetin alfa, and our post hoc analysis suggests that prophylactic heparin could be considered for critically ill patients receiving epoetin alfa.
Supported by Johnson & Johnson Pharmaceutical Research and Development.
Dr. H. Corwin reports receiving consulting and lecture fees from Ortho Biotech and Johnson & Johnson Pharmaceutical Research and Development; Drs. Fabian and May receiving consulting fees from Ortho Biotech; Dr. Pearl receiving lecture fees from Ortho Biotech; Drs. An, Bowers, Burton, and Klausner being employees of Johnson & Johnson Pharmaceutical Research and Development; and Dr. M. Corwin being an employee of BattelleCRO, which is a paid contractor to Johnson & Johnson Pharmaceutical Research and Development. No other potential conflict of interest relevant to this article was reported.
Source Information
From Dartmouth–Hitchcock Medical Center, Lebanon, NH (H.L.C., A.G.); University of Tennessee Health Science Center, Memphis (T.C.F.); Vanderbilt University Medical Center, Nashville (A.M.); Stanford University Medical Center, Stanford, CA (R.G.P.); University of Massachusetts Memorial Medical Center, Worcester (S.H.); Johnson & Johnson Pharmaceutical Research and Development, Raritan, NJ (R.A., P.J.B., P.B., M.A.K.); and Boston University School of Medicine, Boston, and BattelleCRO, Newton, MA (M.J.C.).
Address reprint requests to Dr. Howard Corwin at Dartmouth–Hitchcock Medical Center, 1 Medical Center Dr., Lebanon, NH 03756, or at howard.l.corwin@hitchcock.org.
Members of the EPO (Erythropoietin) Critical Care Trials Group and other participants are listed in the Appendix.
Appendix
Members of the Erythropoietin (EPO) Critical Care Trial Group were as follows: Bay Area Chest Physicians, Clearwater, FL: D. Amin; University of North Dakota, Grand Forks: D. Antonenko; Saint Louis University, St. Louis: J. Bailey; Kettering Medical Center Network, Kettering, OH: R. Barker; University of Michigan Medical Center, Ann Arbor: R. Bartlett; Fairview University, Minneapolis: G. Beilman; Madrona Medical Group, Bellingham, WA: D. Berry; Orlando Regional Medical Center, Orlando, FL: E. Block; R. Adams Cowley Shock Trauma Center, University of Maryland, Baltimore: G. Bochicchio; Medical College of Wisconsin, Milwaukee: K. Brasel; Marietta Pulmonary Medicine–Wellstar Kennestone, Marietta, GA: W. Bray; California Pacific Medical Center, San Francisco: C. Brown; St. Vincent's Hospital, New York: C. Carpati; Santa Teresa Hospital, San Jose, CA: E. Cheng; United Health Services Hospitals, Johnson City, NY: M. Chisdak; University of California at Irvine, Orange: M. Cinat; York Hospital, York, PA: K. Clancy; University of California at San Diego Medical Center, San Diego: R. Coimbra; Louisiana State University Health Sciences Center, Shreveport: S. Conrad; Hershey Medical Center, Hershey, PA: R. Cooney; University of Wisconsin Medical Center, Madison: D. Coursin; Missouri Baptist Medical Center, St. Louis: M. Cox; University of Cincinnati, Cincinnati: K. Davis, Jr.; West Virginia University, Morgantown: H. Dedhia; University of Texas Health Science Center, San Antonio: D. Dent; Memorial Hospital of Rhode Island, Pawtucket: V.A. DePalo; Morristown Memorial Hospital, Morristown, NJ: L.T. DiFazio, Jr.; Denver Health and University of Colorado Health Sciences, Denver: I. Douglas; Research for Health in Erie County, Buffalo, NY: A. El-Solh; University of Tennessee, Memphis: T. Fabian; Inova–Fairfax Hospital, Falls Church, VA: S. Fakhry; Baptist Medical Center, San Antonio, TX: P. Fornos; Overlake Hospital Medical Center, Bellevue, WA: T. Freudenberger; University of Florida–Shands Hospital, Gainesville: T.J. Gallagher; New York Methodist Hospital, Brooklyn: L. George; Cooper University Hospital, Camden, NJ: D. Gerber; Duke University Medical Center, Durham, NC: J. Govert; Legacy Health System, Portland, OR: K.D. Gubler; George Washington University Medical Center, Washington, DC: G. Gutierrez; Massachusetts General Hospital, Boston: R.S. Harris; Spectrum Health Downtown Campus, Grand Rapids, MI: M.J. Harrison; South Alabama Medical Science Foundation, Mobile: M. Hassan; St. Elizabeth's Medical Center, Brighton, MA: G. Hayes; Brooke Army Medical Center, Fort Sam Houston, San Antonio, TX: J. Hayes; University of Massachusetts Memorial Medical Center, Worcester: S.O. Heard; Baystate Medical Center, Springfield, MA: T. Higgins; Henry Ford Medical Center, Detroit: H.M. Horst; Sutter Health, Sacramento, CA: D.P. Ikeda; Emory Healthcare–Emory University School of Medicine, Atlanta: K. Kalassian; St. Vincent's Hospital Worcester Medical Center, Worcester, MA: D. Kaufman; University of Kentucky Chandler Medical Center, Lexington: P. Kearney; St. Luke's–Roosevelt Hospital, New York: H. Khouli; University of Oklahoma, Oklahoma City: G.T. Kinasewitz; University Medical Center, Tucson, AZ: S. Knoper; Mount Sinai School of Medicine, New York: R. Kohli-Seth; Rhode Island Hospital, Providence: M. Levy; St. Thomas Hospital, Nashville: R. Light; Wake Forest University Health Sciences, Winston-Salem, NC: D. MacGregor; West Suburban Hospital, Oak Park, IL: B. Margolis; Harris Methodist Fort Worth Hospital, Fort Worth, TX: L.H. Martinez; Vanderbilt University Medical Center, Nashville: A. May; Oregon Health & Science University, Critical Care, Portland: J. Mayberry; Washington University School of Medicine, St. Louis: J. Mazuski; Alta Bates Summit Medical Center, Berkeley, CA: J. McFeely; St. Jude Medical Center, Fullerton, CA: L. McNabb; Tulane University School of Medicine, New Orleans: N. McSwain; University of Alabama Hospital, Birmingham: S. Melton; Memorial Medical Center, Johnstown, PA: S.L. Miller; University of Kansas Medical Center, Kansas City: M. Moncure; Bay Medical Center, Panama City, FL: T. Moriarty; Memorial Health University Medical Center, Savannah, GA: S. Morris; Wilford Hall Medical Center, Lackland Air Force Base, TX: D. Mueller; Harborview Medical Center, Seattle: M. Neff; King's County Hospital, Brooklyn, NY: P. O'Neill; North Shore University Hospital, Manhasset, NY: D. Ost; Texas Tech University Health Science Center, Odessa: L. Oud; University of Rochester Medical Center, Rochester, NY: P.J. Papadakos; Naval Medical Center San Diego, San Diego, CA: J.S. Parrish; Stanford University Medical Center, Stanford, CA: R. Pearl; Sacred Heart Hospital, Pensacola, FL: D. Phillips; University of Louisville, Louisville, KY: H. Polk; Pulmonary Consultants and Primary Care Physicians' Medical Group, Orange, CA: J. Preston; University of Pittsburgh Medical Center, Pittsburgh: J.C. Puyana; Memorial Hospital, Colorado Springs, CO: R. Rains; Dartmouth–Hitchcock Medical Center, Lebanon, NH: A. Rassias; Maine Medical Center, Portland: R. Riker; Brigham and Women's Hospital, Boston: S. Rogers; University Hospitals of Cleveland, Cleveland: J. Rowbottom; Chest and Critical Care Consultants–Research Division, Anaheim, CA: D.V. Savani; Creighton University Medical Center, Omaha, NE: D. Schuller; University of Miami, Ryder Trauma Center, Miami: C. Schulman; Arizona Pulmonary Specialists, Phoenix: S. Shahryar; Englewood Hospital and Medical Center, Englewood, NJ: A. Shander; Stony Brook University Hospital and Medical Center, Stony Brook, NY: M. Shapiro; Hahnemann University Hospital, Philadelphia: M. Sherman; Yale School of Medicine, New Haven, CT: M. Siegel; Northside Respiratory Care, Atlanta: H. Silverboard; University of Maryland Hospitals, Baltimore: H. Silverman; Piedmont Respiratory Research Foundation, Greensboro, NC: D. Simonds; Winthrop University Hospital, Mineola, NY: P. Spiegler; Presbyterian Hospital, Charlotte, NC: J. Spiers; Southern Illinois University School of Medicine, Springfield: J. Sutyak; Sarasota Memorial Health Care System, Sarasota, FL: J.W. Swisher; MeritCare Hospital, Fargo, ND: M. Tieszen; Arizona Pulmonary Specialists, Scottsdale: A.J. Tillinghast; University of Virginia Health Systems, Charlottesville: J. Truwit; St. Vincent's Hospital and Health Centers, Carmel, IN: P. Vohra; Santa Barbara Cottage Hospital, Santa Barbara, CA: K. Waxman; Northwestern Memorial Hospital, Chicago: M. West; University of Iowa, Iowa City: L. Wibbenmeyer; Grand Valley Internal Medicine, Grand Rapids, MI: J. Wilt; Arizona Pulmonary Specialists, Phoenix: S. Wright; Evanston Northwestern Healthcare, Evanston, IL: T. Wynnychenko; Queen's Medical Center, Honolulu: M. Yu; John Peter Smith Hospital, Fort Worth, TX: D. Ziegler. Other participants in the study were as follows: Principal Investigators — Dartmouth–Hitchcock Medical Center, Lebanon, NH: H.L. Corwin, A. Gettinger; Data and Safety Monitoring Board — State University of New York, Stony Brook: M. Parker, chair; Rush–Presbyterian–St. Luke's Medical Center, Chicago: R. Balk; Pennsylvania Oncology–Hematology Associates, Philadelphia: D. Henry; Massachusetts General Hospital, Boston: D. Schoenfeld; Independent Statistical Review — Harvard School of Public Health, Boston: L.-J. Wei; Data Management — BattelleCRO, Newton, MA; Study Sponsor — Johnson & Johnson Pharmaceutical Research and Development, Raritan, NJ.
- References
References
1
Corwin HL ,Parsonnet KC ,Gettinger A . RBC transfusion in the ICU: is there a reason? Chest 1995;108:767-771
CrossRef | Web of Science | Medline2
Rodriguez RM ,Corwin HL ,Gettinger A ,Corwin MJ ,Gubler D ,Pearl RG . Nutritional deficiencies and blunted erythropoietin response as causes of the anemia of critical illness. J Crit Care 2001;16:36-41
CrossRef | Web of Science | Medline3
Vincent JL ,Baron JF ,Reinhart K , et al. Anemia and blood transfusion in critically ill patients. JAMA 2002;288:1499-1507
CrossRef | Web of Science | Medline4
Corwin HL ,Gettinger A ,Pearl RG , et al. The CRIT Study: anemia and blood transfusion in the critically ill -- current clinical practice in the United States. Crit Care Med 2004;32:39-52
CrossRef | Web of Science | Medline5
Hebert PC ,Wells G ,Blajchman MA , et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med 1999;340:409-417[Erratum, N Engl J Med 1999;340:1056.]
Full Text | Web of Science | Medline6
Napolitano LM ,Corwin HL . Efficacy of red blood cell transfusion in the critically ill. Crit Care Clin 2004;20:255-268
CrossRef | Web of Science | Medline7
Marik PE ,Sibbald WJ . Effect of stored-blood transfusion on oxygen delivery in patients with sepsis. JAMA 1993;269:3024-3029
CrossRef | Web of Science | Medline8
Taylor RW ,O'Brien J ,Trottier SJ , et al. Red blood cell transfusions and nosocomial infections in critically ill patients. Crit Care Med 2006;34:2302-2308
CrossRef | Web of Science | Medline9
Corwin HL ,Krantz S . Anemia in the critically ill: “acute” anemia of chronic disease. Crit Care Med 2000;28:3098-3099
CrossRef | Web of Science | Medline10
Rogiers P ,Zhang H ,Leeman M , et al. Erythropoietin response is blunted in critically ill patients. Intensive Care Med 1997;23:159-162
CrossRef | Web of Science | Medline11
Corwin HL ,Gettinger A ,Rodriguez RM , et al. Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized, double-blind, placebo-controlled trial. Crit Care Med 1999;27:2346-2350
CrossRef | Web of Science | Medline12
Corwin HL ,Gettinger A ,Pearl RG , et al. Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized controlled trial. JAMA 2002;288:2827-2835
CrossRef | Web of Science | Medline13
Coleman T ,Brines M . Recombinant human erythropoietin in critical illness: a role beyond anemia? Crit Care 2004;8:337-341
CrossRef | Web of Science | Medline14
Maiese K ,Li F ,Chong ZZ . New avenues of exploration for erythropoietin. JAMA 2005;293:90-95
CrossRef | Web of Science | Medline15
Brines M ,Cerani A . Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. Kidney Int 2006;70:246-250
CrossRef | Web of Science | Medline16
Henke M ,Laszig R ,Rube C , et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo controlled trial. Lancet 2003;362:1255-1260
CrossRef | Web of Science | Medline17
Leyland-Jones B ,Semiglazov V ,Pawlicki M , et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005;23:5960-5972
CrossRef | Web of Science | Medline18
Bohlius J ,Wilson J ,Seidenfeld J , et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98:708-714
CrossRef | Web of Science | Medline19
Singh AK ,Szczech L ,Tang KL , et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-2098
Full Text | Web of Science | Medline
- Citing Articles (113)
Citing Articles
1
Andreas H. Kramer, Peter Roux. (2012) Red Blood Cell Transfusion and Transfusion Alternatives in Traumatic Brain Injury. Current Treatment Options in Neurology
CrossRef2
Paola Cassis, Lorenzo Gallon, Ariela Benigni, Marilena Mister, Anna Pezzotta, Samantha Solini, Elena Gagliardini, Daniela Cugini, Mauro Abbate, Sistiana Aiello, Federica Rocchetta, Pierangela Scudeletti, Norberto Perico, Marina Noris, Giuseppe Remuzzi. (2012) Erythropoietin, but not the correction of anemia alone, protects from chronic kidney allograft injury. Kidney International
CrossRef3
Christoffer Sølling. (2012) Organ-Protective and Immunomodulatory Effects of Erythropoietin - An Update on Recent Clinical Trials. Basic & Clinical Pharmacology & Toxicology 110:2, 113-121
CrossRef4
Bhanu P. Nalla, John Freedman, Gregory M.T. Hare, C. David Mazer. (2012) Update on Blood Conservation for Cardiac Surgery. Journal of Cardiothoracic and Vascular Anesthesia 26:1, 117-133
CrossRef5
Aurelia Bustos, Ruth Álvarez, Pedro Miguel Aramburo, Francisco Carabantes, Nieves Díaz, Jesús Florián, Martín Lázaro, José María Martín de Segovia, José Antonio Gasquet, Adrián Alegre. (2012) Evaluation of clinical use and effectiveness of darbepoetin alfa in cancer patients with chemotherapy-induced anemia. Current Medical Research and Opinion 28:1, 57-67
CrossRef6
Fred A. Luchette, Michael D. Pasquale, Timothy C. Fabian, Wayne K. Langholff, Marsha Wolfson. (2011) A randomized, double-blind, placebo-controlled study to assess the effect of recombinant human erythropoietin on functional outcomes in anemic, critically ill, trauma subjects: the Long Term Trauma Outcomes Study. The American Journal of Surgery
CrossRef7
Joseph A. Posluszny, Kuzhali Muthumalaiappan, Ameet R. Kini, Andrea Szilagyi, Li-Ke He, Yanxia Li, Richard L. Gamelli, Ravi Shankar. (2011) Burn Injury Dampens Erythroid Cell Production Through Reprioritizing Bone Marrow Hematopoietic Response. The Journal of Trauma: Injury, Infection, and Critical Care 71:5, 1288-1296
CrossRef8
Manfred Nairz, Thomas Sonnweber, Andrea Schroll, Igor Theurl, Günter Weiss. (2011) The pleiotropic effects of erythropoietin in infection and inflammation. Microbes and Infection
CrossRef9
Katerina Pavenski, Gregory M. T. Hare, C. David Mazer. (2011) Erythropoietic neuroprotection: Holy Grail or potential to fail?. Intensive Care Medicine 37:9, 1403-1405
CrossRef10
Ajay K Singh. (2011) Is there a deleterious effect of erythropoietin in end-stage renal disease?. Kidney International 80:6, 569-571
CrossRef11
Giuseppe Curinga, Amit Jain, Michael Feldman, Mark Prosciak, Bradley Phillips, Stephen Milner. (2011) Red blood cell transfusion following burn. Burns 37:5, 742-752
CrossRef12
C. David Mazer, Howard Leong-Poi, Tejinder Chhina, Zuhair Alfardan, Harry Lapierre, Zhilan Wang, Zane S. Jackson, Beiping Qiang, James Mahoney, David Latter, Gregory M.T. Hare, Bradley H. Strauss, Jerome Teitel. (2011) Recombinant factor VIIa affects anastomotic patency of vascular grafts in a rabbit model. The Journal of Thoracic and Cardiovascular Surgery 142:2, 418-423
CrossRef13
Paola Cassis, Nadia Azzollini, Samantha Solini, Marilena Mister, Sistiana Aiello, Daniela Cugini, Pierangela Scudeletti, Elena Gagliardini, Mauro Abbate, Lorenzo Gallon, Giuseppe Remuzzi, Marina Noris. (2011) Both Darbepoetin Alfa and Carbamylated Erythropoietin Prevent Kidney Graft Dysfunction Due to Ischemia/Reperfusion in Rats. Transplantation 92:3, 271-279
CrossRef14
Claudia S. Robertson, Leela Cherian, Mahek Shah, Robert Garcia, Jovany Cruz Navarro, Raymond J. Grill, Carla Cerami Hand, Tian Siva Tian, H. Julia Hannay. (2011) Neuroprotection with an Erythropoietin Mimetic Peptide (pHBSP) in a Model of Mild Traumatic Brain Injury Complicated by Hemorrhagic Shock. Journal of Neurotrauma110727065850006
CrossRef15
Y. Ciccarella, C. Balestra, J. Valsamis, P. Van der Linden. (2011) Increase in endogenous erythropoietin synthesis through the normobaric oxygen paradox in cardiac surgery patients. British Journal of Anaesthesia 106:5, 752-753
CrossRef16
Yaozong Zhang, Xiaolan Du, Lin Chen. (2011) Is there a relationship between bone and critical illness?. Medical Hypotheses 76:5, 615-617
CrossRef17
Ton Lisman, Stephen H. Caldwell, Robert J. Porte. (2011) Anemia as a potential contributor to bleeding in patients with liver disease – Neglected but not forgotten. Journal of Hepatology 54:3, 594-595
CrossRef18
Sébastien Faure. (2011) Érythropoïétines. Actualités Pharmaceutiques 50:503, 55-58
CrossRef19
Rui Maio, Bruno Sepodes, Nimesh S. A. Patel, Christoph Thiemermann, Helder Mota-Filipe, Paulo Costa. (2011) Erythropoietin Preserves the Integrity and Quality of Organs for Transplantation After Cardiac Death. Shock 35:2, 126-133
CrossRef20
Jonathan Cohen, Ilya Kagan, Remos Hershcovici, Sylvianne Bursztein-De Myttenaere, Nicola Makhoul, Alexander Samkohvalov, Moshe Hersch, Sharon Einav, Vadim Berezovsky, Daniel Jorge Jakobson, Pierre Singer. (2011) Red blood cell transfusions—are we narrowing the evidence-practice gap? An observational study in 5 Israeli intensive care units. Journal of Critical Care 26:1, 106.e1-106.e6
CrossRef21
A. Cerami. (2011) The value of failure: the discovery of TNF and its natural inhibitor erythropoietin. Journal of Internal Medicine 269:1, 8-15
CrossRef22
Sotirios Kakavas, Theano Demestiha, Panagiotis Vasileiou, Theodoros Xanthos. (2011) Erythropoetin as a novel agent with pleiotropic effects against acute lung injury. European Journal of Clinical Pharmacology 67:1, 1-9
CrossRef23
William J. Mauermann, Dawit T. Haile, Randall P. Flick. 2011. Blood Conservation. , 395-417.
CrossRef24
Matilde Lombardero, Kalman Kovacs, Bernd W. Scheithauer. (2011) Erythropoietin: A Hormone with Multiple Functions. Pathobiology 78:1, 41-53
CrossRef25
Z. Madrazo-González, A. García-Barrasa, L. Rodríguez-Lorenzo, A. Rafecas-Renau, G. Alonso-Fernández. (2011) Anemia and transfusion therapy: an update. Medicina Intensiva (English Edition) 35:1, 32-40
CrossRef26
Christophe Lelubre, Jean-Louis Vincent. (2011) Red blood cell transfusion in the critically ill patient. Annals of Intensive Care 1:1, 43
CrossRef27
Manfred Nairz, Andrea Schroll, Alexander R. Moschen, Thomas Sonnweber, Milan Theurl, Igor Theurl, Nicole Taub, Christina Jamnig, Daniela Neurauter, Lukas A. Huber, Herbert Tilg, Patrizia L. Moser, Günter Weiss. (2011) Erythropoietin Contrastingly Affects Bacterial Infection and Experimental Colitis by Inhibiting Nuclear Factor-κB-Inducible Immune Pathways. Immunity 34:1, 61-74
CrossRef28
Nimesh SA Patel, Massimo Collino, Muhammad M Yaqoob, Christoph Thiemermann. (2011) Erythropoietin in the intensive care unit: beyond treatment of anemia. Annals of Intensive Care 1:1, 40
CrossRef29
L. Velly, L. Pellegrini, B. Guillet, N. Bruder, P. Pisano. (2010) Erythropoietin 2nd cerebral protection after acute injuries: A double-edged sword?. Pharmacology & Therapeutics 128:3, 445-459
CrossRef30
Aron F. Popov, Egbert G. Schulz, Jan D. Schmitto, Kasim O. Coskun, Mladen V. Tzvetkov, Stephan Kazmaier, Janna Zimmermann, Friedrich A. Schöndube, Michael Quintel, José Hinz. (2010) Relation Between Renal Dysfunction Requiring Renal Replacement Therapy and Promoter Polymorphism of the Erythropoietin Gene in Cardiac Surgery. Artificial Organs 34:11, 961-968
CrossRef31
Tim Walsh. 2010. Anemia and Red Blood Transfusion in Critical Care. , 476-489.
CrossRef32
Nabil E. Hassan, John Winters, Kim Winterhalter, Diann Reischman, Yasser El-Borai. (2010) Effects of blood conservation on the incidence of anemia and transfusions in pediatric parapneumonic effusion: A hospitalist perspective. Journal of Hospital Medicine 5:7, 410-413
CrossRef33
Jeremy M. Kahn, Gordon D. Rubenfeld. (2010) Financial disclosures in clinical practice guidelines. Critical Care Medicine 38:8, 1755-1756
CrossRef34
Ajay K. Singh. (2010) Diabetes, Anemia and CKD: Why TREAT?. Current Diabetes Reports 10:4, 291-296
CrossRef35
Nancy M. Heddle. (2010) The randomized controlled trial: in celebration of TRANSFUSION's 50th. Transfusion 50:6, 1173-1178
CrossRef36
ERHABOR OSARO, CHIMA NJEMANZE. (2010) Challenges of meeting the future blood transfusion requirement in England and Wales. Autologous blood transfusion could become an adjunct to the UK blood transfusion program in the future. Transfusion Alternatives in Transfusion Medicine 11:2, 72-81
CrossRef37
Jeffrey F. Barletta, Brad Cooper, Martin J. Ohlinger. (2010) Adverse drug events associated with disorders of coagulation. Critical Care Medicine 38, S198-S218
CrossRef38
Rafael Fernandez, Isabel Tubau, Jordi Masip, Luz Muñoz, Inmaculada Roig, Antonio Artigas. (2010) Low Reticulocyte Hemoglobin Content Is Associated with a Higher Blood Transfusion Rate in Critically Ill Patients. Anesthesiology 112:5, 1211-1215
CrossRef39
William T. Abraham, Inder S. Anand, Marc Klapholz, Piotr Ponikowski, Debra Scarlata, Scott M. Wasserman, Dirk J. Van Veldhuisen. (2010) Treatment of Anemia With Darbepoetin Alfa in Heart Failure. Congestive Heart Failure 16:3, 87-95
CrossRef40
Rose S. Cohen, Paula Karlin, Madeline Yushak, Donna Mancini, Mathew S. Maurer. (2010) The Effect of Erythropoietin on Exercise Capacity, Left Ventricular Remodeling, Pressure-Volume Relationships, and Quality of Life in Older Patients With Anemia and Heart Failure With Preserved Ejection Fraction. Congestive Heart Failure 16:3, 96-103
CrossRef41
Jelena Roganovic. (2010) Transfusions in the critically ill pediatric patient. Pediatric Health 4:2, 201-208
CrossRef42
K. Reinhart, F.M. Brunkhorst, H.-G. Bone, J. Bardutzky, C.-E. Dempfle, H. Forst, P. Gastmeier, H. Gerlach, M. Gründling, S. John, W. Kern, G. Kreymann, W. Krüger, P. Kujath, G. Marggraf, J. Martin, K. Mayer, A. Meier-Hellmann, M. Oppert, C. Putensen, M. Quintel, M. Ragaller, R. Rossaint, H. Seifert, C. Spies, F. Stüber, N. Weiler, A. Weimann, K. Werdan, T. Welte. (2010) Prävention, Diagnose, Therapie und Nachsorge der Sepsis. Der Anaesthesist 59:4, 347-370
CrossRef43
K. Reinhart, F.M. Brunkhorst, H.-G. Bone, J. Bardutzky, C.-E. Dempfle, H. Forst, P. Gastmeier, H. Gerlach, M. Gründling, S. John, W. Kern, G. Kreymann, W. Krüger, P. Kujath, G. Marggraf, J. Martin, K. Mayer, A. Meier-Hellmann, M. Oppert, C. Putensen, M. Quintel, M. Ragaller, R. Rossaint, H. Seifert, C. Spies, F. Stüber, N. Weiler, A. Weimann, K. Werdan, T. Welte. (2010) Prävention, Diagnose, Therapie und Nachsorge der Sepsis. Intensivmedizin und Notfallmedizin 47:3, 185-207
CrossRef44
Joseph A. Posluszny, Richard L. Gamelli. (2010) Anemia of Thermal Injury: Combined Acute Blood Loss Anemia and Anemia of Critical Illness. Journal of Burn Care & Research 31:2, 229-242
CrossRef45
Ran Schwarzkopf, Christine Chung, Justin J. Park, Michael Walsh, Jeffrey M. Spivak, David Steiger. (2010) Effects of Perioperative Blood Product Use on Surgical Site Infection Following Thoracic and Lumbar Spinal Surgery. Spine 35:3, 340-346
CrossRef46
Thomas L. Ortel. (2010) Acquired thrombotic risk factors in the critical care setting. Critical Care Medicine 38, S43-S50
CrossRef47
Jiyeol Yoon, Sungmin Kim, Soo Chan Lee, Hongsub Lim. (2010) Postoperative High-Dose Intravenous Iron Sucrose with Low Dose Erythropoietin Therapy after Total Hip Replacement. The Korean Journal of Internal Medicine 25:4, 454
CrossRef48
George C. Velmahos. (2010) Erythropoiesis and the Mystery of an Unexplained Survival Benefit. Annals of Surgery 251:1, 5
CrossRef49
Peep Talving, Thomas Lustenberger, Leslie Kobayashi, Kenji Inaba, Galinos Barmparas, Beat Schnüriger, Lydia Lam, Linda S. Chan, Demetrios Demetriades. (2010) Erythropoiesis Stimulating Agent Administration Improves Survival After Severe Traumatic Brain Injury. Annals of Surgery 251:1, 1-4
CrossRef50
D. L. Hershman, D. L. Buono, J. Malin, R. McBride, W. Y. Tsai, A. I. Neugut. (2009) Patterns of Use and Risks Associated With Erythropoiesis-Stimulating Agents Among Medicare Patients With Cancer. JNCI Journal of the National Cancer Institute 101:23, 1633-1641
CrossRef51
Bizhan Aarabi, J Marc Simard. (2009) Traumatic brain injury. Current Opinion in Critical Care 15:6, 548-553
CrossRef52
Lena M. Napolitano, Stanley Kurek, Fred A. Luchette, Howard L. Corwin, Philip S. Barie, Samuel A. Tisherman, Paul C. Hebert, Gary L. Anderson, Michael R. Bard, William Bromberg, William C. Chiu, Mark D. Cipolle, Keith D. Clancy, Lawrence Diebel, William S. Hoff, K Michael Hughes, Imtiaz Munshi, Donna Nayduch, Rovinder Sandhu, Jay A. Yelon. (2009) Clinical practice guideline: Red blood cell transfusion in adult trauma and critical care*. Critical Care Medicine 37:12, 3124-3157
CrossRef53
Gil Hardy, Ana Maria Menendez, William Manzanares. (2009) Trace element supplementation in parenteral nutrition: Pharmacy, posology, and monitoring guidance. Nutrition 25:11-12, 1073-1084
CrossRef54
Felicita Andreotti, Luciano Agati, Elena Conti, Eleonora Santucci, Teresa Rio, Federica Tarantino, Luigi Natale, Daniele Berardi, Antonella Mattatelli, Beatrice Musumeci, Lorenzo Bonomo, Massimo Volpe, Filippo Crea, Camillo Autore. (2009) Update on phase II studies of erythropoietin in acute myocardial infarction. Rationale and design of Exogenous erythroPoietin in Acute Myocardial Infarction: New Outlook aNd Dose Association Study (EPAMINONDAS). Journal of Thrombosis and Thrombolysis 28:4, 489-495
CrossRef55
Biren Saraiya, Susan Goodin. (2009) Management of Venous Thromboembolism and the Potential to Impact Overall Survival in Patients with Cancer. Pharmacotherapy 29:11, 1344-1356
CrossRef56
Jonathan Marinaro, Jessica Smith, Isaac Tawil, Mary Billstrand, Kendall P. Crookston. (2009) HBOC-201 use in traumatic brain injury: case report and review of literature. Transfusion 49:10, 2054-2059
CrossRef57
Yanlu Zhang, Ye Xiong, Asim Mahmood, Yuling Meng, Changsheng Qu, Timothy Schallert, Michael Chopp. (2009) Therapeutic effects of erythropoietin on histological and functional outcomes following traumatic brain injury in rats are independent of hematocrit. Brain Research 1294, 153-164
CrossRef58
Deborah J Cook, James Douketis, Donald Arnold, Mark A Crowther. (2009) Bleeding and venous thromboembolism in the critically ill with emphasis on patients with renal insufficiency. Current Opinion in Pulmonary Medicine 15:5, 455-462
CrossRef59
Lauralyn McIntyre, Alan Tinmouth. (2009) Restrictive red blood cell transfusion and alternatives to transfusion in the critically ill: a review of the clinical evidence. Therapy 6:5, 747-757
CrossRef60
Julia Bohlius, Kurt Schmidlin, Corinne Brillant, Guido Schwarzer, Sven Trelle, Jerome Seidenfeld, Marcel Zwahlen, Mike J Clarke, Olaf Weingart, Sabine Kluge, Margaret Piper, Maryann Napoli, Dirk Rades, David Steensma, Benjamin Djulbegovic, Martin F Fey, Isabelle Ray-Coquard, Volker Moebus, Gillian Thomas, Michael Untch, Martin Schumacher, Matthias Egger, Andreas Engert, Julia Bohlius. 2009. Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data. .
CrossRef61
Marie-Louise Otterman, Johanna M. Nijboer, Iwan C. C. van der Horst, Matijs van Meurs, Henk-Jan ten Duis, Maarten W. N. Nijsten. (2009) Reticulocyte Counts and Their Relation to Hemoglobin Levels in Trauma Patients. The Journal of Trauma: Injury, Infection, and Critical Care 67:1, 121-124
CrossRef62
Brendan J. Doyle, Charanjit S. Rihal, Dennis A. Gastineau, David R. Holmes. (2009) Bleeding, Blood Transfusion, and Increased Mortality After Percutaneous Coronary Intervention. Journal of the American College of Cardiology 53:22, 2019-2027
CrossRef63
Howard L. Corwin, Andrew F. Shorr. (2009) Red blood cell transfusion in the critically ill: When is it time to say enough?*. Critical Care Medicine 37:6, 2114-2116
CrossRef64
Shivak Sharma, Brian F. Gage, Elena Deych, Michael W. Rich. (2009) Anemia: An independent predictor of death and hospitalizations among elderly patients with atrial fibrillation. American Heart Journal 157:6, 1057-1063
CrossRef65
Susan Margulies, Ramona Hicks. (2009) Combination Therapies for Traumatic Brain Injury: Prospective Considerations. Journal of Neurotrauma 26:6, 925-939
CrossRef66
David J. Murphy, David Howard, Angela Muriithi, Pedro Mendez-Tellez, Jonathan Sevransky, Carl Shanholtz, Giora Netzer, Peter J. Pronovost, Dale M. Needham. (2009) Red blood cell transfusion practices in acute lung injury: What do patient factors contribute?*. Critical Care Medicine 37:6, 1935-1940
CrossRef67
Kathleen D. Liu. (2009) Critical Care Nephrology: Core Curriculum 2009. American Journal of Kidney Diseases 53:5, 898-910
CrossRef68
Alistair D. Nichol, D. James Cooper. (2009) Can we improve neurological outcomes in severe traumatic brain injury?. Injury 40:5, 471-478
CrossRef69
Julia Bohlius, Kurt Schmidlin, Corinne Brillant, Guido Schwarzer, Sven Trelle, Jerome Seidenfeld, Marcel Zwahlen, Michael Clarke, Olaf Weingart, Sabine Kluge, Margaret Piper, Dirk Rades, David P Steensma, Benjamin Djulbegovic, Martin F Fey, Isabelle Ray-Coquard, Mitchell Machtay, Volker Moebus, Gillian Thomas, Michael Untch, Martin Schumacher, Matthias Egger, Andreas Engert. (2009) Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. The Lancet 373:9674, 1532-1542
CrossRef70
Andreas H. Kramer, David A. Zygun, Thomas P. Bleck, Aaron S. Dumont, Neal F. Kassell, Bart Nathan. (2009) Relationship Between Hemoglobin Concentrations and Outcomes Across Subgroups of Patients with Aneurysmal Subarachnoid Hemorrhage. Neurocritical Care 10:2, 157-165
CrossRef71
Lena M. Napolitano. (2009) Epoetin alfa in the critically ill: What dose? Which route?*. Critical Care Medicine 37:4, 1501-1503
CrossRef72
Alejandro C. Arroliga, Kalpatha K. Guntupalli, Jessica S. Beaver, Wayne Langholff, Kimberly Marino, Kathleen Kelly. (2009) Pharmacokinetics and pharmacodynamics of six epoetin alfa dosing regimens in anemic critically ill patients without acute blood loss*. Critical Care Medicine 37:4, 1299-1307
CrossRef73
Gregory M. T. Hare, James E. Baker, C. David Mazer. (2009) Perioperative management of acute and chronic anemia: has the pendulum swung too far?. Canadian Journal of Anesthesia/Journal canadien d'anesthésie 56:3, 183-189
CrossRef74
Amy C. Fox, Craig M. Coopersmith. (2009) Erythropoietin in sepsis: A new use for a familiar drug?*. Critical Care Medicine 37:3, 1138-1139
CrossRef75
Stuart A. McCluskey, Wing K. Cheung, Rita Katznelson, Humara Poonawala, Ludwik Fedorko, George Djaiani, Bobby Mehta, Keyvan Karkouti. (2009) The pharmacokinetic profile of recombinant human erythropoietin is unchanged in patients undergoing cardiac surgery. European Journal of Clinical Pharmacology 65:3, 273-279
CrossRef76
Kazutetsu Aoshiba, Shigemitsu Onizawa, Takao Tsuji, Atsushi Nagai. (2009) Therapeutic effects of erythropoietin in murine models of endotoxin shock*. Critical Care Medicine 37:3, 889-898
CrossRef77
Fredric M. Pieracci, Peter Henderson, John Rocco Macmillan Rodney, Daniel N. Holena, Alicia Genisca, Ivan Ip, Steven Benkert, Lynn J. Hydo, Soumitra R. Eachempati, Jian Shou, Philip S. Barie. (2009) Randomized, Double-Blind, Placebo-Controlled Trial of Effects of Enteral Iron Supplementation on Anemia and Risk of Infection during Surgical Critical Illness. Surgical Infections 10:1, 9-19
CrossRef78
Florian Simon, Enrico Calzia, Peter Radermacher, Hubert Schelzig. (2009) BENEFICIAL EFFECTS OF ERYTHROPOIETIN IN MODELS OF SHOCK AND ORGAN FAILURE-NOTHING IS SIMPLE AND EASY. Shock 31:2, 220-221
CrossRef79
J. E. Morley, S. D. Anker, W. J. Evans. (2009) Cachexia and aging: An update based on the fourth international cachexia meeting. The Journal of Nutrition, Health and Aging 13:1, 47-55
CrossRef80
N.K. Kanakaris, G. Petsatodis, B. Chalidis, N. Manidakis, G. Kontakis, P.V. Giannoudis. (2009) The role of erythropoietin in the acute phase of trauma management: Evidence today. Injury 40:1, 21-27
CrossRef81
A. Harrois, J. Duranteau. 2009. Choc hémorragique. , 505-522.
CrossRef82
N. Magasich, P. Van der Linden. 2009. Transfusion sanguine. , 357-369.
CrossRef83
N. Lameire, W. van Biesen, E. Hoste, R. Vanholder. (2008) The prevention of acute kidney injury an in-depth narrative review: Part 2: Drugs in the prevention of acute kidney injury. NDT Plus 2:1, 1-10
CrossRef84
Gretchen M. Brophy, Valerie Sheehan, Marc J. Shapiro, Lawrence Lottenberg, Debra Scarlata, Paul Audhya. (2008) A US multicenter, retrospective, observational study of erythropoiesis-stimulating agent utilization in anemic, critically ill patients admitted to the intensive care unit. Clinical Therapeutics 30:12, 2324-2334
CrossRef85
Mark Crowther, Ghazala Radwi. (2008) Erythropoietin-Stimulating Agents: Ongoing Concerns With Safety. American Journal of Kidney Diseases 52:6, 1039-1041
CrossRef86
Wanja M Bernhardt, Kai-Uwe Eckardt. (2008) Physiological basis for the use of erythropoietin in critically ill patients at risk for acute kidney injury. Current Opinion in Critical Care 14:6, 621-626
CrossRef87
Roland N. Dickerson. (2008) Nutrition Support Pharmacist - Supporting Literature for an Evidence-Based Metabolic Support Practice. Hospital Pharmacy 43:11, 928-936
CrossRef88
M. Brines, A. Cerami. (2008) Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. Journal of Internal Medicine 264:5, 405-432
CrossRef89
James E Novak, Lynda A Szczech. (2008) Triumph and tragedy: anemia management in chronic kidney disease. Current Opinion in Nephrology and Hypertension 17:6, 580-588
CrossRef90
C. Schultz, J. Zimmer, C. Härtel, J. Rupp, P. Temming, T. Strunk. (2008) Attenuation of monocyte proinflammatory cytokine responses to Neisseria meningitidis in children by erythropoietin. Clinical & Experimental Immunology 154:2, 187-191
CrossRef91
T. Steinmetz, U. Totzke, U. Söling, M. Groschek, J. Mittermüller, M. Schweigert, H. Tesch, S. Nawka, S. Schmitz, A. Tsamaloukas. (2008) Hemoglobin levels that trigger erythropoiesis-stimulating agent treatment decisions for cancer-associated anemia – examination of practice in Germany. Current Medical Research and Opinion 24:10, 2751-2756
CrossRef92
Neeraj Agarwal, Josef T. Prchal. (2008) Erythropoietic Agents and the Elderly. Seminars in Hematology 45:4, 267-275
CrossRef93
Gregory M. T. Hare, Albert K. Y. Tsui, Anya T. McLaren, Tenille E. Ragoonanan, Julie Yu, C David Mazer. (2008) Anemia and Cerebral Outcomes: Many Questions, Fewer Answers. Anesthesia & Analgesia 107:4, 1356-1370
CrossRef94
Kwame Asare. (2008) Anemia of Critical Illness. Pharmacotherapy 28:10, 1267-1282
CrossRef95
Charles J. Diskin, Thomas J. Stokes, Linda M. Dansby, Lautrec Radcliff, Thomas B. Carter. (2008) Beyond Anemia: The Clinical Impact of the Physiologic Effects of Erythropoietin. Seminars in Dialysis 21:5, 447-454
CrossRef96
Lena M. Napolitano, Timothy C. Fabian, Kathleen M. Kelly, Jeffrey A. Bailey, Ernest F. Block, Wayne Langholff, Christopher Enny, Howard L. Corwin. (2008) Improved Survival of Critically Ill Trauma Patients Treated With Recombinant Human Erythropoietin. The Journal of Trauma: Injury, Infection, and Critical Care 65:2, 285-299
CrossRef97
Sigismond Lasocki, Sarah Millot, Valérie Andrieu, Philippe Lettéron, Nathalie Pilard, Françoise Muzeau, Olivier Thibaudeau, Philippe Montravers, Carole Beaumont. (2008) Phlebotomies or erythropoietin injections allow mobilization of iron stores in a mouse model mimicking intensive care anemia. Critical Care Medicine 36:8, 2388-2394
CrossRef98
Abhinav Diwan, Andrew G. Koesters, Devan Capella, Hartmut Geiger, Theodosia A. Kalfa, Gerald W. Dorn. (2008) Targeting erythroblast-specific apoptosis in experimental anemia. Apoptosis 13:8, 1022-1030
CrossRef99
Kenneth Maiese, Zhao Zhong Chong, Faqi Li, Yan Chen Shang. (2008) Erythropoietin: Elucidating new cellular targets that broaden therapeutic strategies. Progress in Neurobiology 85:2, 194-213
CrossRef100
Y. ROBINSON. (2008) Evidence-based management of anaemia in severely injured patients. Acta Anaesthesiologica Scandinavica 52:5, 587-590
CrossRef101
Daniel Seehofer, Ulf P. Neumann, Anja Schirmeier, Jessica Carter, Si-Young Ria Cho, Andri Lederer, Nada Rayes, Michael D. Menger, Andreas K. Nüssler, Peter Neuhaus. (2008) Synergistic effect of erythropoietin but not G-CSF in combination with curcumin on impaired liver regeneration in rats. Langenbeck's Archives of Surgery 393:3, 325-332
CrossRef102
Martin Dunkelgrun, Sanne E. Hoeks, Gijs M.J.M. Welten, Radosav Vidakovic, Tamara A. Winkel, Olaf Schouten, Ron T. van Domburg, Jeroen J. Bax, Ruud Kuijper, Michael Chonchol, Hence J.M. Verhagen, Don Poldermans. (2008) Anemia as an Independent Predictor of Perioperative and Long-Term Cardiovascular Outcome in Patients Scheduled for Elective Vascular Surgery. The American Journal of Cardiology 101:8, 1196-1200
CrossRef103
Kenneth Maiese. (2008) Triple play: Promoting neurovascular longevity with nicotinamide, WNT, and erythropoietin in diabetes mellitus. Biomedicine & Pharmacotherapy 62:4, 218-232
CrossRef104
Joel Michels Topf. (2008) CERA: third-generation erythropoiesis-stimulating agent. Expert Opinion on Pharmacotherapy 9:5, 839-849
CrossRef105
Kenneth Maiese, Zhao Zhong Chong, Yan Chen Shang. (2008) Raves and risks for erythropoietin. Cytokine & Growth Factor Reviews 19:2, 145-155
CrossRef106
Murat O. Arcasoy. (2008) The non-haematopoietic biological effects of erythropoietin. British Journal of Haematology 141:1, 14-31
CrossRef107
(2008) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 17:3, i-xii
CrossRef108
Kenneth Maiese. (2008) Diabetic stress: new triumphs and challenges to maintain vascular longevity. Expert Review of Cardiovascular Therapy 6:3, 281-284
CrossRef109
Derek J. Linderman, William J. Janssen. (2008) Critical Care Medicine for the Hospitalist. Medical Clinics of North America 92:2, 467-479
CrossRef110
Sang-Min Lee. (2008) Critical Care Medicine. Tuberculosis and Respiratory Diseases 65:3, 169
CrossRef111
K Nayan S Rao, Azan S Binbrek, Burton E Sobel. (2008) Heart disease and erythropoietin. Future Cardiology 4:1, 57-64
CrossRef112
(2007) Epoetin Alfa in Critically Ill Patients. New England Journal of Medicine 357:24, 2515-2517
Full Text113
Cook, Deborah, Crowther, Mark, . (2007) Targeting Anemia with Erythropoietin during Critical Illness. New England Journal of Medicine 357:10, 1037-1039
Full Text
- Letters
